Halozyme begins dosing in Phase III trial of PEGPH20 combination to treat pancreatic cancer
US-based Halozyme Therapeutics has begun a Phase III clinical trial (Halo-301) of its investigational drug, PEGPH20, in combination with Abraxane (nab-paclitaxel) and gemcitabine for previously untreated metastatic pancreatic cancer patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Abraxane | Cancer | Cancer & Oncology | Clinical Trials | Pancreas | Pancreatic Cancer | Pharmaceuticals